Table 3.
Cytokine production capacity.
| 24-hour stimulation | Controls | Patients |
|---|---|---|
| LPS stimulated PBMCs | ||
| TNFα, pg/mL | 637 [414-1204] | 324 [212-976] |
| IL-1β, pg/mL | 5222 [3893-11317] | 6950 [4808-11264] |
| IL-6, ng/mL | 13.1 [7.9-15.8] | 12.0 [6.9-20.8] |
| IL-8, ng/mL | 107 [89-123] | 110 [68-139] |
| IL-10, pg/mL | 182 [91-295] | 110 [59-236] |
| P3C stimulated PBMCs | ||
| TNFα, pg/mL | 557 [88-1338] | 338 [145-681] |
| IL-1β, pg/mL | 4216 [3112-5929] | 5230 [3982-6720] |
| IL-6, ng/mL | 13.2 [11.3-17.4] | 13.6 [10.8-17.6] |
| IL-8, ng/mL | 148 [129-189] | 146 [126-185] |
| IL-10, pg/mL | 47 [47-131] | 55 [47-97] |
| 7-day stimulation | ||
| C. albicans stimulated PBMCs | ||
| IFNγ, pg/mL | 1500 [727-1500] | 1276 [625-1500] |
| IL-17, pg/mL | 1509 [631-2811] | 1033 [575-2137] |
| IL-22, pg/mL | 5855 [2723-9233] | 3803 [1120-9906] |
| S. aureus stimulated PBMCs | ||
| IFNγ, pg/mL | 1500 [604-1500] | 1040 [508-1500] |
| IL-17, pg/mL | 171 [39-401] | 77 [39-127] |
| IL-22, pg/mL | 472 [108-661] | 189 [85-787] |
Cytokine production capacity of PBMCs in control participants (n = 14) and participants with periodontitis (n = 14) after 24h stimulation with LPS or P3C to assess the innate immune response, and 7d stimulation with C. albicans or S. aureus to assess the adaptive immune response. Data are reported as median with [interquartile ranges], p-values are age corrected using ANCOVA.